Feb 11, 2019
CytRx Corporation Highlights Majority of Cancer Patients Do Not Have Targetable Genetic Mutations and Are Therefore Candidates for Chemotherapy
Jan 14, 2019
CytRx Corporation Highlights Aldoxorubicin's Inclusion In New NantCell Inc. Colorectal Cancer Clinical Trial
Dec 21, 2018
CytRx Corporation Announces Conclusion of Pre-Clinical Phase for Its Albumin Binding Ultra High Potency LADR(TM) Drug Candidates and Accompanying Companion Diagnostic
Nov 28, 2018
CytRx Corporation to Present at the 11th Annual LD Micro Main Event
Nov 08, 2018
CytRx Corporation Highlights NantCell Inc's Clinical Data with Aldoxorubicin Presented at the Society for Immunotherapy of Cancer's 33rd Annual Meeting
Nov 02, 2018
CytRx Corporation Reports Third Quarter 2018 Financial Results
Oct 31, 2018
Key Emerging Oncology Trends By Big Pharma Strengthen CytRx's Rationally Designed, Targeted Therapies Pipeline
Oct 29, 2018
CytRx to Hold Third Quarter 2018 Financial Results Conference Call and Webcast on Friday, November 2, 2018
Sep 25, 2018
CytRx Corporation to Present at the 2018 MicroCap Conference
Sep 13, 2018
CytRx Corporation Announces Receipt of Milestone Payment from Orphazyme A/S
Aug 27, 2018
CytRx Corporation to Present at the H.C. Wainwright & Co. 20th Annual Global Investment Conference in New York City September 4-6, 2018
Aug 06, 2018
CytRx Corporation Reports Second Quarter 2018 Financial Results
Aug 01, 2018
CytRx Corporation Pays Off Balance of Outstanding Debt
Jul 30, 2018
CytRx Corporation to Hold Second Quarter 2018 Financial Results Conference Call and Webcast on Monday, August 6, 2018
Jul 25, 2018
CytRx Announces Centurion BioPharma Corporation's Filing of a Provisional Patent Application
Jul 23, 2018
CytRx Corporation Announces Expiration of Outstanding Warrants
Jul 16, 2018
CytRx Corporation to Present at the Singular Research Summer Solstice 2018 Conference
Jun 28, 2018
CytRx Corporation Highlights Aldoxorubicin Included in New NantCell Inc. Triple Negative Breast Cancer Clinical Trial
Jun 25, 2018
CytRx Corporation Joins Russell Microcap® Index
Jun 21, 2018
CytRx Corporation Highlights Review of NantCell Inc's Aldoxorubicin Published in Future Oncology